Categories: Business News

LANXESS expands range of membranes for reverse osmosis

  • New Lewabrane high performance membrane elements for brackish water treatment
  • Product launch at AMTA/AWWA Membrane Technology Conference & Exposition in New Orleans, Louisiana/USA

Cologne, January 29, 2018: Specialty chemicals company LANXESS is expanding its range of membrane elements for reverse osmosis (RO). The new Lewabrane HP (high performance) series comprises elements that consist of an enhanced brackish water membrane to serve applications in which high rejection and energy efficiency are important. Using the new types in combination with monodisperse Lewatit ion exchange resins provides high quality produced water at lower operational cost.

With an average salt rejection of 99.7 percent (at 2,000 ppm NaCl; 225 psi) and high permeability, the new product types are a further development of the high cross-linked polyamide membrane which LANXESS launched in 2012. Controlling the degree of polyamide cross-linking during production process provides a small effective “pore size” that results in high rejection of solutes, regardless their charge. “By optimization of the process, the flux could be improved without compromising permeate quality. Therefore, high rejection, even at changing feed parameters like pH or salinity, can be achieved at high flux rate,” explains Dr. Jens Lipnizki, head of Technical Marketing Membranes in the Liquid Purification Technologies business unit.

LANXESS is showcasing its new Lewabrane HP membrane elements for the first time at the Membrane Technology Conference & Exposition, hosted by the American Membrane Technology Association (AMTA) and the American Water Works Association (AWWA) in New Orleans (LA), USA, February 25 to 28, 2019.

Efficient even at changing conditions

Reverse osmosis is used for desalination and purification of water and has been growing rapidly in industrial, municipal and waste water reuse applications, where parameters can change quickly. The Lewabrane HP types ensure high rejection of critical ions even at changing temperature and pH levels. Depending on the application, different species are rated as critical. For boiler feed water silica is critical, while wastewater applications focus on nitrate or organics.

“In a number of industries high salt rejection combined with high energy efficiency is useful. Especially if the RO process is designed in combination with another separation process like ion exchange. The benefit is based on the lower applied pressure and on the higher rejection, which lead to longer cycle times of the ion exchange units,” says Lipnizki. Therefore, the typical applications are combined processes like production of boiler feed water for power generation, zero liquid discharge processes (ZLD), or production of ultrapure water. Yet, the product can also be used in innovative processes like closed circuit reverse osmosis (CCRO), in which the feed water composition changes with each cycle, the constant rejection is an important benefit of the new Lewabrane HP type.

Well designed

LewaPlus, the engineering tool developed by LANXESS, enables easy and reliable design of water treatment facilities. The software allows designing ion exchange and RO membrane based plants separately as well as combined systems. It pools the knowledge and experience of LANXESS in both technologies and is giving plant designers a recommendation on how they can best arrange the membrane components to their needs. The latest 2.0.9 version already includes the new Lewabrane HP types.

Detailed information about the products can be obtained online at www.lpt.lanxess.com. The LewaPlus software can also be downloaded from this website free of charge. 

Forward-Looking Statements

This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person’s officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.

LANXESS is a leading specialty chemicals company with sales of EUR 9.7 billion in 2017. The company currently has about 15,500 employees in 33 countries and is represented at 59 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Corporate Comm India(CCI Newswire)

The Pharma Times News Bureau

Recent Posts

8 Ways Insomnia Affects Skin Health & How To Avoid It

By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…

23 hours ago

Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and Treatment

Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…

23 hours ago

Healthcare Startups to Watch Out for in 2025

New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…

2 days ago

DKMS’s First Global Impact Report of 2023 Serves as New Ray of Hope for Blood Cancer Patients Worldwide

National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…

2 days ago

Sterling Biotech to start world’s first precision fermentation-based dairy protein factory in Gujarat

Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…

3 days ago

Pioneers in Senior Care, Antara, Partners with Leading Diagnostics Player Dr. Lal PathLabs to Strengthen its Geriatric Care Services

New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…

3 days ago